RT Journal Article
SR Electronic
T1 Synergistic Benefit of Adoptive T Cells in Combination With Chemoradiotherapy Against Metastatic Prostate Cancer Cells
JF Anticancer Research
JO Anticancer Res
FD International Institute of Anticancer Research
SP 3427
OP 3434
DO 10.21873/anticanres.15829
VO 42
IS 7
A1 YUN-CHU SHEN
A1 HUNG-JEN SHIH
A1 CHI-CHIEN LIN
A1 SHENG-HSIEN HUANG
A1 SHENG-CHUAN WU
A1 CHI-HAO HSIAO
A1 SHAO-CHI CHIU
A1 DER-YANG CHO
A1 CHIN-PAO CHANG
A1 YUEH PAN
A1 PING-HSIAO SHIH
YR 2022
UL http://ar.iiarjournals.org/content/42/7/3427.abstract
AB Background/Aim: Prostate cancer (PC) is one of the major diseases that affects male health and ranks as the second most frequent cancer in men worldwide. Although most newly-diagnosed PCs are well-differentiated tumors with a high cure probability, there are some patients with aggressive malignancies that show potential for recurrence and metastasis. Cytotoxic T lymphocytes are a specific immune effector cell population that mediates immune responses against cancer. Materials and Methods: In the present study, the cytotoxicity of peripheral blood mononuclear cells (PBMCs)-derived γδ T cells and cytokine-induced killer (CIK) cells in combination with chemoradiotherapy against PC cells was evaluated using Alamar blue cell viability and cell membrane permeability assays. Results: Advanced PC-3 cells, which were more resistant to docetaxel (Doc), also showed higher viability following pretreatment with radiation. The cell proliferation inhibition was significantly increased upon additional γδ T or CIK treatment. Furthermore, the proportion of apoptotic cells was significantly (p<0.05) increased in the Doc-γδ T cell co-treatment group as compared with the Doc or γδ T cell treated alone group. Conclusion: γδ T cell therapy may provide additional benefit compared to traditional chemoradiotherapy for PC treatment.